

CTI - Women's Health February 2010

Adis Clinical Trials Insight: Presented at Meetings – Women's Health

The table below highlights some of trials presented during sessions at the meetings described.

Annual San Antonio Breast Cancer Symposium (32nd : December 2009 : San Antonio, Texas, USA)

Adis CTI Record	Drug(s)	Purpose	Study Results	Sponsor
1 803006008	Anastrozole Goserelin Tamoxifen Zoledronic-acid	This study compared the cost effectiveness goserelin + anastrozole or tamoxifen +/- zoledronic acid for the treatment of premenopausal women with hormone-receptor-positive early breast cancer from the perspectives of the healthcare systems in Sweden, Norway, Denmark, and Finland.	Goserelin + anastrozole or tamoxifen + zoledronic acid appeared to be cost effective compared with goserelin + anastrozole or tamoxifen for the treatment of premenopausal women with hormone receptor-positive early breast cancer in in Sweden, Norway, Denmark, and Finland. The addition of zoledronic acid resulted in incremental costs per quality-adjusted life-year gained of EUR1510, EUR2162, EUR3369 and EUR3494 for Norway, Sweden, Finland and Denmark, respectively.	Novartis Pharmaceuticals Corporation
2 803003845	Cyclophosphamide Docetaxel Doxorubicin Fluorouracil Methotrexate	This study investigated the efficacy of docetaxel with or after doxorubicin-based adjuvant therapy followed by cyclophosphamide + methotrexate + fluorouracil (CMF), compared with docetaxel + CMF alone, in patients with lymph node-positive breast cancer. Results after a median 8 years follow-up are reported here.	Docetaxel with or after doxorubicin may provide additional benefits to cyclophosphamide + fluorouracil + methotrexate (CMF) at long-term follow-up in patients with lymph node-positive breast cancer. At median follow-up of 9 years, docetaxel with or after doxorubicin followed by CMF, compared with regimens with no docetaxel, appeared to increase disease free survival (hazard ratio 0.91; 95% 0.81, 1.05) and overall survival (hazard ratio 0.91; 95% 0.77, 1.08).	sanofi-aventis

Adis Clinical Trials Insight: Ongoing Trials – Status Tracking February 2010

The table below highlights the Large (>100), Randomised Phase III & IV ongoing trials whose status has changed during February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
1 700024334		Completed	IV	Musculoskeletal pain: treatment Cost-utility analysis Manual treatment vs advice promoting self management in Denmark	
2 700014595		Active, no longer recruiting	III	Deep vein thrombosis: treatment Assessing cost-effectiveness of elastic compression stockings	SIGVARIS Corp

CTI - Women's Health February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
3 700043890		Recruiting	IV	Bipolar disorders: treatment Cost-effectiveness and quality-of-life effects of a chronic care management	
4 700046415		Active, no longer recruiting	IV	Uterine leiomyoma: treatment Cost-analysis trial of ExAblate surgery compared with myomectomy for the enhancement of fertility In women with unexplained infertility and who have non-hysteroscopically resectable disease	InSightec
5 700041315		Completed	III	Prostate cancer: treatment Comparing cost-effectiveness of radical prostatectomy versus palliative expectant management In patients with clinically localised disease	
6 700050232		Discontinued	IV	Dementia: treatment Evaluating impact of dementia advisors on the quality of life of dementia sufferers Comparing cost-effectiveness of dementia advisor program with information provision alone	
7 700051273		Recruiting	IV	Bronchiolitis: treatment Comparing continuous versus intermittent pulse oxymetry on hospital cost and length of stay in neonates and infants	
8 700051882		Recruiting	IV	Back pain, sciatica: treatment Efficacy and costs of spinal cord stimulation with Precision SCS system versus reoperation In patients with failed back surgery syndrome; EVIDENCE trial	Boston Scientific Corporation
9 700047392		Active, no longer recruiting	IV	Stroke: treatment Assessing cost-effectiveness of a structured, training programme for caregivers to improve patient outcomes	
10 700051581	ACE-inhibitors Angiotensin-receptor-antagonists Bisoprolol Carvedilol	Recruiting	IV	Angiotensin receptor antagonists, ACE inhibitors, bisoprolol, carvedilol: therapeutic use Heart failure Improving prescribing patterns in heart failure patients by providing active specialist support and educational material to primary care physicians	
11 700051431	Alternative-medicine	Recruiting	IV	Depressive disorders: treatment Efficacy and cost-effectiveness of acupuncture, counselling Compared with usual general practitioner care	

CTI - Women's Health February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
12 700031925	Analgesics	Completed	IV	Analgesics: therapeutic use Musculoskeletal pain Evaluating prescribing patterns in patients with chronic disease: Efficacy, cost-effectiveness and resource use	
13 700033460	Antihypertensives Candesartan-cilexetil Chlortalidone Hydrochlorothiazide Indapamide Losartan Losartan/hydrochlorothiazide Olmesartan-medoxomil Telmisartan Trichlormethiazide Valsartan	Recruiting	III	Losartan/hydrochlorothiazide vs antihypertensives: therapeutic use Hypertension Phase III trial focusing on patient compliance: the COMFORT trial	
14 700039449	Antineoplastics	Recruiting	III	Antineoplastics: treatment Colorectal cancer Phase III trial alone or in combination with surgery in patients with asymptomatic metastatic disease: Cost-analysis	
15 700048117	Antiparkinsonians	Active, no longer recruiting	IV	Antiparkinsonians: therapeutic use Parkinsonism, essential tremor Assessing changes in prescribing pattern after DaTSCAN™ imaging in patients with clinically uncertain disease	GE Healthcare
16 700040216	Human-papillomavirus-vaccine-recombinant-quadrivalent	Recruiting	III	Human papillomavirus vaccine recombinant quadrivalent: therapeutic use Prevention of human papillomavirus infections, cervical cancer Phase III trial in underserved African American adolescent females: Drug-utilisation trial	Merck & Co
17 70005522	Ibandronic-acid Zoledronic-acid	Completed	III	Ibandronic acid vs zoledronic acid: therapeutic use Bone metastases In patients with malignant and painful bone disease	Roche
18 700025170	Levonorgestrel	Completed	IV	Levonorgestrel: therapeutic use Prevention of pregnancy Drug utilisation and quality-of-life effects in patients after vaginal delivery	
19 700049741	Levosimendan	Recruiting	IV	Levosimendan: therapeutic use	

CTI - Women's Health February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
20 700033917	Mannitol	Recruiting	III	Mannitol: therapeutic use Bronchiectasis Efficacy and quality-of-life effects	Pharmaxis
21 700021202	Metoprolol	Recruiting	IV	Metoprolol: therapeutic use Secondary prevention of myocardial infarction In combination with pacemaker in patients with slow heart rates after myocardial infarction: efficacy and quality-of-life analysis	
22 700046508	Misoprostol Oxytocin	Completed	III	Misoprostol vs oxytocin: therapeutic use Prevention of perioperative haemorrhage, postpartum haemorrhage Cost-effectiveness trial in women undergoing caesarean section	
23 700025898	Sirolimus	Completed	IV	Sirolimus: therapeutic use Prevention of coronary artery restenosis Cost effectiveness of drug-eluting vs bare metal stents in patients with diabetes	Cordis Corporation
24 700043562	Tranexamic-acid	Recruiting	III	Tranexamic acid: therapeutic use Postpartum haemorrhage Evaluating effects on death, hysterectomy and other relevant outcomes: Cost-effectiveness trial	

For further information, please call +44 (0) 20 7981 0765 or send an e-mail to clientsupport@wolterskluwer.com.